Dulaglutide - Eli Lilly and Company
Alternative Names: LY-2189265; TrulicityLatest Information Update: 04 Feb 2025
At a glance
- Originator Eli Lilly and Company
- Class Antihyperglycaemics; Glucagon-like peptides; Immunoglobulin Fc fragments; Recombinant fusion proteins
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Type 2 diabetes mellitus
Most Recent Events
- 10 Jan 2025 Eli Lilly and Company initiates enrolment in a phase III AWARD-PEDS PLUS trial for Type 2 diabetes mellitus (In Children, In adolescents) in USA (SC) in January 2025 (NCT06739122, H9X-MC-GBGS)
- 24 Dec 2024 Eli Lilly and Company plans a phase III AWARD-PEDS PLUS trial for Type 2 diabetes mellitus (In Children, In adolescents) in USA (SC) in January 2025 (NCT06739122)
- 30 Sep 2024 Annovis files three new patents for a combination therapy involving Buntanetap, Trulicity, and Viagra